A. Baines

Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double‐blind, placebo‐controlled study

P. Anand, A. Krishen, R. Lai, 2013, European journal of pain.

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler

W. De Backer, D. Kelleher, A. Preece, 2015, Journal of aerosol medicine and pulmonary drug delivery.

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

R. Beasley, P. Daley-Yates, I. Braithwaite, 2018, Respiratory Research.

The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma.

P. Thomas, R. Kempsford, R. Ravindranath, 2016, Respiratory medicine.

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

P. Daley-Yates, J. Fingleton, G. Bardsley, 2022, Respiratory Research.

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

P. Anand, B. Chizh, J. Palmer, 2011, European journal of pain.

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

M. Minden, G. Borthakur, O. Barbash, 2019, Blood.

Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.

M. Weatherall, R. Beasley, J. Pilcher, 2016, Respiratory medicine.

702 A RANDOMISED, TWO‐PERIOD CROSS‐OVER STUDY TO INVESTIGATE THE EFFICACY OF THE TRPV1 ANTAGONIST SB‐705498 IN ACUTE MIGRAINE

B. Chizh, J. Palmer, J. Appleby, 2009 .